Finzati - Logo
LGND logo

Ligand Pharmaceuticals Incorporated

LGND • Biotechnology
$0.00
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$5.99B
Growth
3.6%
Cash Flow
4/5
Trend
Mostly stable
Evidence
Stable or improving margins · 46.4%Positive free cash flow · 2.53Consistent free cash flow · 4/5Manageable debt level · 0.44Healthy liquidity · 22.23
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:58 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.00
Change0.00%
Market Cap$5.99B
52W Range137.14 - 326.63
Beta1.07
Gross Margin97.54%
Oper. Margin17.61%
Profit Margin46.42%
Debt/Eq0.44
Current Ratio22.23
Quick Ratio21.98
Revenue 5Y3.61%

Investment DNA

How strong this company looks for long-term investors

64
out of 100
Business Quality
Margins, moat, returns
84/100
Financial Strength
Debt, cash, stability
74/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
39/100
Why this score▼
Stable or improving margins · 46.4%Positive free cash flow · 2.53Consistent free cash flow · 4/5Manageable debt level · 0.44Healthy liquidity · 22.23Negative growth trend

Analyst view

Analyst sentiment and price target

Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-08-07
Low
$326.00
Mean
$340.20
Median
$340.00
High
$358.00

Company Overview

IPO: 11/18/1992
Industry: Biotechnology
P/B i: 3.59
Debt / Equity i: 0.44
Operating Margin: 17.61%
Net Margin: 46.42%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.44
Current Ratio: 22.23
Quick Ratio: 21.98
Status: Good

Insider Transactions

Recent executive and insider activity

Reardon Andrew
Transaction: 08/03/2026
SELL
Change
-5,000
Price
$52.27
Filing
08/04/2026
Type
SELL
Reardon Andrew
Transaction: 08/03/2026
SELL
Change
-409
Price
$292.82
Filing
08/04/2026
Type
SELL
Reardon Andrew
Transaction: 07/01/2026
SELL
Change
-5,000
Price
$52.27
Filing
07/06/2026
Type
SELL